Watson's Nabumetone Tablets Receive FDA Approval

Watson Pharmaceuticals, Inc. WPI today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for Nabumetone Tablets USP, 500 mg and 750 mg. Watson expects to launch the product shortly. Nabumetone had total U.S. sales of $58 million for the twelve months ending April 30, 2011, according to IMS Health. Nabumetone is indicated for the relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.